CSF2 and congenital rubella syndrome: showed that CAR T-cells combined with lenzilumab, a GM-CSF neutralizing antibody, or CRISPR-Cas9 generated GM-CSFKO CAR T-cells reduced CRS and neuroinflammation (42).